Onxeo announces the great success of its share capital increase with shareholders’ preferential subscription rights
Total demand of Approximately 76.4 million euros, i.e. an oversubscription rate of 216% of the offer Full exercise of the […]
Total demand of Approximately 76.4 million euros, i.e. an oversubscription rate of 216% of the offer Full exercise of the […]
BioAlliance Pharma SA (Euronext Paris – BIO), an innovative Company specialized in the development of drugs in orphan oncology diseases, […]
BioAlliance Pharma SA (Euronext Paris – BIO), an innovative Company specialized in the development of drugs in orphan oncology diseases, […]
Positive Phase II preliminary results of Validive® For the prevention of Severe Oral Mucositis in Head and Neck cancer patients […]
BioAlliance Pharma SA (Euronext Paris – BIO), an innovative Company specialized in the development of drugs in orphan oncology diseases, […]
BioAlliance Pharma SA (Euronext Paris – BIO), an innovative Company specialized in the development of drugs in orphan oncology diseases, […]
2013: Significant progress on key strategic programs • Livatag® phase III (ReLive): European expansion and authorization from the FDA to […]
BioAlliance Pharma SA (Euronext Paris – BIO), Société d’innovation spécialisée dans le développement de médicaments visant des pathologies orphelines en […]
— Combined company expected to have increased scale and a highly complementary pipeline of late-stage products addressing significant unmet medical […]
BioAlliance Pharma SA (Euronext Paris – BIO), an innovative Company specialized in the development of drugs in orphan oncology diseases, […]
DEFINITIVE MERGER PLAN BETWEEN BIOALLIANCE PHARMA AND TOPOTARGET COMBINED ENTITY TO BE NAMED ONXEO — Onxeo expected to have a […]
BioAlliance Pharma SA (Euronext Paris – BIO), an innovative Company specialized in the development of drugs in orphan oncology diseases, […]
BioAlliance Pharma SA (Euronext Paris – BIO), an innovative company specialized in the development of drugs in orphan oncology diseases, […]
BioAlliance Pharma SA (Euronext Paris – BIO), an innovative company specializing in the development of drugs for orphan oncology diseases, […]
BioAlliance Pharma SA (Euronext Paris – BIO), an innovative Company specialized in the development of drugs in orphan oncology diseases, […]
BioAlliance Pharma SA (Euronext Paris – BIO), an innovative company specialized in the development of drugs in orphan oncology diseases, […]
Suite à l’annonce conjointe des deux sociétés le 23 juillet 2014, BioAlliance Pharma SA (Euronext Paris – BIO), société innovante […]
Major evolution of the Company, renamed Onxeo, resulting from the merger between BioAlliance Pharma and Topotarget Good progress of the […]
Onxeo SA (Euronext Paris, NASDAQ OMX Copenhagen – ONXEO), an innovative company specialized in the development of drugs for orphan […]
Onxeo S.A. (Euronext Paris, NASDAQ OMX Copenhagen: ONXEO), an innovative biopharmaceutical company specialized in the development of orphan oncology drugs, […]
Quarterly Information as of September 30, 2014 – Effective integration of both entities, BioAlliance Pharma and Topotarget, into newly named […]
Onxeo SA (Euronext Paris, Nasdaq OMX Copenhagen – ONXEO or “the Company”), an innovative biopharmaceutical company specialized in the development […]
Onxeo SA (Euronext Paris, NASDAQ OMX Copenhagen – ONXEO), an innovative company specializing in the development of orphan oncology drugs, […]
Onxeo SA (Euronext Paris, NASDAQ OMX Copenhagen – ONXEO), an innovative company specializing in the development of orphan oncology drugs, […]
Onxeo S.A. (Euronext Paris, NASDAQ OMX Copenhagen: ONXEO), an innovative biopharmaceutical company specialized in the development of orphan oncology drugs, […]
Onxeo SA (Euronext Paris, NASDAQ OMX Copenhagen – ONXEO), an innovative company specialized in the development of drugs for orphan […]
BioAlliance Pharma SA (Euronext Paris – BIO), Société d’innovation spécialisée dans le développement de médicaments visant des pathologies orphelines en […]
• Accelerated Approval of Topotarget’s Beleodaq™ for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma • Early […]
BioAlliance Pharma SA (Euronext Paris – BIO), an innovative Company specialized in the development of drugs in orphan oncology diseases, […]
BioAlliance Pharma SA (Euronext Paris – BIO), an innovative Company specialized in the development of drugs in orphan oncology diseases, […]
BioAlliance Pharma SA (Euronext Paris – BIO), an innovative Company specialized in the development of drugs in orphan oncology diseases, […]
BioAlliance Pharma SA (Euronext Paris – BIO), an innovative Company specialized in the development of drugs in orphan oncology diseases, […]
BioAlliance Pharma SA (Euronext Paris – BIO), an innovative Company specialized in the development of drugs in orphan oncology diseases, […]
BioAlliance Pharma SA (Euronext Paris – BIO), an innovative Company specialized in the development of drugs in orphan oncology diseases, […]
BioAlliance Pharma SA (Euronext Paris – BIO), an innovative Company dedicated to the development of orphan oncology products, announced major […]
Paris, February 4, 2014 – BioAlliance Pharma SA (Euronext Paris – BIO), an innovative Company dedicated to the development of orphan […]
BioAlliance Pharma SA (Euronext Paris – BIO), an innovative Company dedicated to the development of orphan oncology products, announced today […]
BioAlliance Pharma SA (Euronext Paris – BIO), an innovative Company dedicated to the development of orphan oncology, announced today that […]